Clinical Trial Detail

NCT ID NCT02384746
Title Phase I Study of the Combination of MLN9708 and Fulvestrant
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Dartmouth-Hitchcock Medical Center
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Ixazomib

Age Groups: adult

Additional content available in CKB BOOST